Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ruo-xian Deng
Preclinical Evaluation of the Efficacy, Pharmacokinetics and Immunogenicity of JS-001, a Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody
Acta Pharmacologica Sinica
Medicine
Pharmacology
Related publications
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
PD-1 Receptor (PDCD1; PD-1; CD279); Programmed Cell Death 1 Ligand 1 (CD274 Molecule; PD-L1; B7-H1)
Science-Business eXchange
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1)
American Journal of Surgical Pathology
Anatomy
Forensic Medicine
Pathology
Surgery
Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers
British Journal of Cancer
Cancer Research
Oncology
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Cancer immunology research
Cancer Research
Immunology
Identification of a Monoclonal Antibody That Targets PD-1 in a Manner Requiring PD-1 Asn58 Glycosylation
Communications Biology
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
